Pharmaceutical company · DSNKY

Daiichi Sankyo
clinical trial
pipeline

Registry checked

Published

Oncology is the largest mapped primary therapeutic group, with 60 of 68 active trials. This ranking covers mapped groups only. Trastuzumab Deruxtecan is linked to 15 distinct active studies, with 2 Phase 1, 9 Phase 3, 4 without a recorded phase. Datopotamab Deruxtecan is linked to 8 distinct active studies, with 2 Phase 1, 1 Phase 2, 4 Phase 3, 1 without a recorded phase.

Phase 2 study NCT04433234 in Duchenne Muscular Dystrophy lists estimated primary completion on 31 January 2027. Phase 2 study NCT04145622 in Advanced Solid Tumor and Malignant Solid Tumor lists estimated primary completion on 30 April 2027. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

68active trials
as lead sponsor
  • Phase 118
  • Phase 218
  • Phase 321
  • Phase 40
  • Phase not recorded11

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

1411 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

02Primary completion

Primary completion moved earlier by 756 days

2032-03-23 (estimated)2030-02-26 (estimated)
23 Mar 203226 Feb 2030

A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

NCT07022483 · ClinicalTrials.gov
Recorded by ComplyRx
28 Oct 2026
Registry last updated
27 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020100011
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-071010021
2026-10-081000011
2026-10-090000000
2026-10-100001011
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-160100011
2026-10-171000011
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-210000000
2026-10-220000000
2026-10-230001011
2026-10-240000000
2026-10-250000000
2026-10-260100011
2026-10-270110021
2026-10-280100121
2026-10-291000011
2026-10-300000000
2026-10-310000000
Type totals452211411 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Trastuzumab Deruxtecan

Enhertu

15
Active trials
11
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 20
  • Phase 39
  • Phase 40
  • Phase not recorded4
Studied condition
Advanced Breast Cancer · Advanced Cancer · Breast Cancer
Next primary completion
01 October 2027 · estimated
Open drug

Datopotamab Deruxtecan

datroway

8
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 21
  • Phase 34
  • Phase 40
  • Phase not recorded1
Studied condition
Advanced or Metastatic NSCLC · Bladder Cancer · Hormone Receptor Positive Breast Cancer
Next primary completion
Not reported
Open drug

Ifinatamab Deruxtecan

Canonical investigational asset

6
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 24
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Solid Tumor · Esophageal Squamous Cell Carcinoma · Extensive Stage-small Cell Lung Cancer
Next primary completion
30 April 2027 · estimated
Open drug

Patritumab deruxtecan

Canonical investigational asset

5
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 23
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Solid Tumor · Bladder Cancer · Breast Cancer
Next primary completion
01 September 2027 · estimated
Open drug

Quizartinib

Canonical investigational asset

4
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 22
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Acute Myeloid Leukemia · Hepatic Impairment · Leukemia
Next primary completion
01 May 2027 · estimated
Open drug

Raludotatug Deruxtecan

Canonical investigational asset

4
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 21
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Solid Tumor · Endometrioid Epithelial Ovarian · Fallopian Tube Cancer
Next primary completion
Not reported
Open drug

61 of 68 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 61 of 68 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Daiichi Sankyo trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
DS-5141b

NCT04433234

Phase 2 · Active, not recruiting

Trial source and qualifications

Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy

Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon, end-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

Start clipped at the display horizon. End clipped at the display horizon.

0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

No eligible observations recorded in the inspected period.

    Start: 30 Jun 2020 · actual
    Primary completion: 31 Jan 2027 · estimated
    Study completion: 31 Jan 2031 · estimated

    2021202220232024202520262027202820292030
    Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
    Ifinatamab Deruxtecan

    NCT04145622

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

    Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

    Start clipped at the display horizon.

    4 candidate observations · 2 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    2 inspected observations omitted. At most three verified observations are shown, not full history.

    • status flip · Recorded 2026-10-07 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
    • enrollment change · Recorded 2026-10-07 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 03 Nov 2019 · actual
    Primary completion: 30 Apr 2027 · estimated
    Study completion: 31 Oct 2029 · estimated

    2021202220232024202520262027202820292030
    Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
    Quizartinib

    NCT03793478

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

    Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

    Start clipped at the display horizon.

    1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    1 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 15 Aug 2018 · actual
      Primary completion: 01 May 2027 · estimated
      Study completion: 01 May 2027 · estimated

      2021202220232024202520262027202820292030
      A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
      Ifinatamab Deruxtecan

      NCT06362252

      Phase 2 · Recruiting

      Trial source and qualifications

      A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      3 candidate observations · 1 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

      • pc date moved · Recorded 2026-10-02 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

      Start: 22 Jul 2024 · actual
      Primary completion: 20 Jul 2027 · estimated
      Study completion: 20 Feb 2028 · estimated

      2021202220232024202520262027202820292030
      A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
      Patritumab deruxtecan

      NCT06172478

      Phase 2 · Recruiting

      Trial source and qualifications

      A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 26 Feb 2024 · actual
        Primary completion: 01 Sept 2027 · estimated
        Study completion: 10 Oct 2028 · estimated

        2021202220232024202520262027202820292030
        Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
        Trastuzumab Deruxtecan

        NCT05950945

        Phase 3 · Recruiting

        Trial source and qualifications

        Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

        0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        No eligible observations recorded in the inspected period.

          Start: 30 Dec 2023 · actual
          Primary completion: 01 Oct 2027 · estimated
          Study completion: 01 Oct 2027 · estimated

          2021202220232024202520262027202820292030

          Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

          6 selected of 29 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 8 actual primary completions, 0 untyped primary completions, 1 past estimates, 1 outside the horizon, 0 contradictory dates.

          04 / Therapeutic focus

          Where the activity is

          60

          active trials in Oncology

          Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

          Active trials by primary therapeutic area

          • Oncology60 trials
          • Gastroenterology & Hepatology1 trials
          • Metabolic/Endocrine/Nutrition1 trials
          • Neurology1 trials
          • Unmapped5 trials
          • Healthy volunteers0 trials

          Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

          06 / Related companies

          All companies
          M

          Merck

          Shared indexed programme context · 3 selected assets

          A

          AstraZeneca

          Shared indexed programme context · 2 selected assets

          Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

          Sources, scope and methodology

          ClinicalTrials.gov lead-sponsor scope

          Canonical current-owner attribution covers 469 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Daiichi Sankyo. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

          ClinicalTrials.gov

          Attribution coverage

          475 distinct registry candidates produced 469 accepted studies. 0 mapped to other owners, 6 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 21 unverified, 21 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

          Indexed enrichment

          429 scoped records have indexed enrichment and 40 do not. Missing enrichment does not remove a trial from cohort counts.

          Scope observation

          The successful attribution check completed at 2026-11-01T06:06:55.129Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot b09bec4ac7b9f690170781a23510ce44fb8261f5148cd1bc009f3045cbb3e006.

          Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

          Dated canonical-attribution snapshot: 469 mapped lead-sponsored clinical studies across all statuses. 429 have indexed enrichment, 40 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

          Keep following
          what matters.

          Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

          Build your watch

          Choose what to track in the watch builder.